These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29403289)

  • 1. Association of clinicopathologic characteristics and outcomes with
    Boostani F; Dolatkhah R; Fakhrjou A; Farassati F; Sanaat Z
    Onco Targets Ther; 2018; 11():449-457. PubMed ID: 29403289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
    Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
    BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High EZH2 Protein Expression Is Associated with Poor Overall Survival in Patients with Luminal A Breast Cancer.
    Jang SH; Lee JE; Oh MH; Lee JH; Cho HD; Kim KJ; Kim SY; Han SW; Kim HJ; Bae SB; Lee HJ
    J Breast Cancer; 2016 Mar; 19(1):53-60. PubMed ID: 27066096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
    Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
    Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
    Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
    Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
    JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
    Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
    BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.
    Debeb BG; Gong Y; Atkinson RL; Sneige N; Huo L; Gonzalez-Angulo AM; Hung MC; Valero V; Ueno NT; Woodward WA
    J Exp Clin Cancer Res; 2014 Jul; 33(1):58. PubMed ID: 25051981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer.
    Dong M; Fan XJ; Chen ZH; Wang TT; Li X; Chen J; Lin Q; Wen JY; Ma XK; Wei L; Ruan DY; Lin ZX; Liu Q; Wu XY; Wan XB
    Oncol Rep; 2014 Sep; 32(3):1101-7. PubMed ID: 25017254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of lymph node-negative breast cancer: Association with clinicopathological factors and tumor associated gene expression.
    He J; Wang H; Ma F; Feng F; Lin C; Qian H
    Oncol Lett; 2014 Oct; 8(4):1717-1724. PubMed ID: 25202398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
    Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
    Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
    Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
    Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.
    Wang X; Cai L; Ye F; Li M; Ma L; Geng C; Song Z; Liu Y
    Medicine (Baltimore); 2019 Sep; 98(36):e16937. PubMed ID: 31490377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer.
    Zhao Y; Yang N; Wang X; Huang Y; Zhou X; Zhang D
    Clin Transl Oncol; 2020 Dec; 22(12):2275-2285. PubMed ID: 32447641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis.
    Wang X; Hu B; Shen H; Zhou H; Xue X; Chen Y; Chen S; Han Y; Yuan B; Zhao H; Zhi Q; Kuang Y
    Biomed Pharmacother; 2015 Oct; 75():218-25. PubMed ID: 26271144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Meng X; Huang Z; Wang R; Jiao Y; Li H; Xu X; Feng R; Zhu K; Jiang S; Yan H; Yu J
    Radiat Oncol; 2014 Aug; 9():188. PubMed ID: 25159232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.
    Bense RD; Sotiriou C; Piccart-Gebhart MJ; Haanen JBAG; van Vugt MATM; de Vries EGE; Schröder CP; Fehrmann RSN
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27737921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma.
    Singla N; Krabbe LM; Aydin AM; Panwar V; Woldu SL; Freifeld Y; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Bagrodia A; Kapur P; Margulis V
    Urol Oncol; 2018 Jul; 36(7):343.e1-343.e8. PubMed ID: 29748098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.